How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,836 results for

Wart Treatment

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts

, however unique problems posed by large or extensive genital warts are not so easily solved and treatment of affected patients remains very challenging. Recurrences are common especially among immune-compromised women. This study will test whether giving the quadrivalent human papilloma virus (HPV) vaccine to women with extensive genital warts prior to surgical treatment will improve outcomes. Investigators hypothesize that pre-treatment with HPV vaccine can play a role in the control of both malignant (...) and benign HPV disease in women with and without HIV infection through stimulation of the antibody response. In addition, HPV types and other associated diseases will be studied in women receiving HPV vaccine and placebo. Condition or disease Intervention/treatment Phase Genital Warts Biological: Quadrivalent HPV vaccine Biological: Hepatitis B vaccine Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 75 participants

2016 Clinical Trials

182. Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts

: Cutanea Life Sciences, Inc. Collaborator: Leiden University Medical Center Information provided by (Responsible Party): Cutanea Life Sciences, Inc. Study Details Study Description Go to Brief Summary: The purpose of this study is to assess the pharmacodynamics, safety and efficacy of omiganan in patients with external genital warts. Condition or disease Intervention/treatment Phase Condylomata Acuminata (External) Drug: Omiganan (CLS001) topical gel Drug: Vehicle topical gel Phase 2 Study Design Go (...) to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 24 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Parallel-Group Study to Explore the Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts Study Start

2016 Clinical Trials

183. Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common Warts

: Dr. Reddys Laboratories, SA Information provided by (Responsible Party): Dr. Reddys Laboratories, SA Study Details Study Description Go to Brief Summary: DFD05 vs. Active01 in the treatment of common warts Condition or disease Intervention/treatment Phase Common Warts Drug: DFD05 Cream Drug: Active01 Cream Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 50 participants Allocation: Randomized Intervention Model (...) Measures : The proportion of subjects categorized as treatment responders (defined as having at least 91% reduction in surface area, averaged across all target warts) [ Time Frame: Visit 5 (week 12) ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study

2016 Clinical Trials

184. Biofields Therapy on Warts

to magnetize). The "fake" biofield therapist, placebo, has been trained to replicate gestures during a training validated by an independent recognized biofield therapist. Condition or disease Intervention/treatment Phase Wart Energy Medecine Magnetism Other: True Biofield therapy Other: Fake Biofield therapy Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 62 participants Allocation: Randomized Intervention Model: Parallel (...) Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: Effect of the Intervention of Biofields Therapy on Warts of the Hands and Feet in Adults: a Prospective, Randomized, Double-blind Trial Study Start Date : April 2016 Actual Primary Completion Date : November 2018 Actual Study Completion Date : November 2018 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment

2016 Clinical Trials

185. Warts, Nongenital (Treatment)

Warts, Nongenital (Treatment) Nongenital Warts Treatment & Management: Medical Care, Surgical Care Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTEzMzMxNy10cmVhdG1lbnQ= processing > Nongenital Warts Treatment (...) & Management Updated: Jun 05, 2018 Author: Philip D Shenefelt, MD, MS; Chief Editor: William D James, MD Share Email Print Feedback Close Sections Sections Nongenital Warts Treatment Medical Care Multiple modalities are available for the treatment of warts, but none is uniformly effective. [ , ] Start with the least painful, least expensive, and least time-consuming methods. Reserve the more expensive and invasive procedures for refractory extensive warts. Immunosuppressed individuals often are refractory

2014 eMedicine.com

186. Warts, Genital (Treatment)

Warts, Genital (Treatment) Human Papillomavirus (HPV) Treatment & Management: Approach Considerations, Considerations in Specific Patient Subgroups, Pharmacologic Therapy Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache (...) =aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjE5MTEwLXRyZWF0bWVudA== processing > Human Papillomavirus (HPV) Treatment & Management Updated: Feb 05, 2019 Author: Peter A Gearhart, MD; Chief Editor: Pranatharthi Haran Chandrasekar, MBBS, MD Share Email Print Feedback Close Sections Sections Human Papillomavirus (HPV) Treatment Approach Considerations There is no single curative treatment for condylomata acuminata. [ ] Eradication or reduction of symptoms is the primary goal of treating warts, but elimination of dysplastic lesions is the goal in treating

2014 eMedicine.com

187. Urethral Warts (Treatment)

Urethral Warts (Treatment) Urethral Warts: Overview, Epidemiology, HPV Transmission Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvNDQzMDA2LW92ZXJ2aWV3 processing > Urethral Warts Updated: Oct 19, 2018 Author (...) with the development of genital tract and anal cancers. [ ] Immunosuppression is associated with reactivation of HPV, increasing the risk of malignant transformation. Patients at risk of developing malignancies may benefit from therapy aimed at eradicating genital warts. [ , , , ] However, medical treatments aimed at treating urethral warts should generally be used with caution, and they should be used only when the warts are easily accessible, as in the fossa navicularis. Podophyllin is contraindicated during

2014 eMedicine.com

188. Warts, Genital (Treatment)

Warts, Genital (Treatment) Genital Warts Treatment & Management: Approach Considerations, Consultations, Prevention Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvNzYzMDE0LXRyZWF0bWVudA== processing > Genital (...) Warts Treatment & Management Updated: Oct 16, 2018 Author: Delaram Ghadishah, MD; Chief Editor: William D James, MD Share Email Print Feedback Close Sections Sections Genital Warts Treatment Approach Considerations Symptomatic treatment may be warranted in emergency situations. Use pressure to stop bleeding, if present. Relieve urethral obstruction (rare). Search for evidence of coexistent STDs; treat them if found and indicated. Further treatment, screening, and vaccination guidelines from

2014 eMedicine Emergency Medicine

189. Warts, Plantar (Treatment)

Warts, Plantar (Treatment) Nongenital Warts Treatment & Management: Medical Care, Surgical Care Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTEzMzMxNy10cmVhdG1lbnQ= processing > Nongenital Warts Treatment (...) & Management Updated: Jun 05, 2018 Author: Philip D Shenefelt, MD, MS; Chief Editor: William D James, MD Share Email Print Feedback Close Sections Sections Nongenital Warts Treatment Medical Care Multiple modalities are available for the treatment of warts, but none is uniformly effective. [ , ] Start with the least painful, least expensive, and least time-consuming methods. Reserve the more expensive and invasive procedures for refractory extensive warts. Immunosuppressed individuals often are refractory

2014 eMedicine Emergency Medicine

190. Covid-19: ASRM Recommendations For Reducing The Risk Of Viral Transmission During Fertility Treatment With The Use Of Autologous Gametes

Covid-19: ASRM Recommendations For Reducing The Risk Of Viral Transmission During Fertility Treatment With The Use Of Autologous Gametes Recommendations for reducing the risk of viral transmission during fertility treatment with the use of autologous gametes: a committee opinion The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Thisdocumentprovidesstrategies,basedonscienti?cprinciplesandclinicalexperience (...) to a center with protocols in place to manage such patients (1). The guidelines in this document provide strategies,basedonscienti?cprinciples and clinical experience, for reducing theriskofvirustransmissionincouples seeking treatment from fertility clinics. Recommendations are aimed at the following: 1) reducing viral load in in- fected partner(s); 2) reducing exposure and susceptibility of a non-infected partner; and 3) promoting frank, de- tailed discussions with patients about available scienti?c

2020 Society for Assisted Reproductive Technology

191. Imiquimod cream 2.5% and 3.75% applied once daily to treat external genital warts in men. (Abstract)

Imiquimod cream 2.5% and 3.75% applied once daily to treat external genital warts in men. We assess the safety and efficacy of imiquimod cream 3.75% and 2.5% in men with external genital warts (EGWs). Two multicenter, randomized, double-blind, placebo-controlled studies were conducted in a total of 447 (225 from study 1 and 222 from study 2) male patients (aged ≥12 years) with 2 to 30 EGWs and a total wart area of 150 mm2 or greater. Participants were randomized (2:2:1) to imiquimod cream 3.75 (...) % or 2.5% or placebo applied once daily until complete clearance or a maximum of 8 weeks (end of treatment [EOT]). There was an 8-week follow-up period (end of study [EOS]) for participants who did not achieve complete clearance by EOT. Participants who achieved complete clearance were observed for an additional 12 weeks. The primary efficacy end point was complete clearance rate. Safety assessments included visual assessment of local skin reactions, number and duration of required rest periods

2015 Cutis Controlled trial quality: predicted high

192. Efficacy and Tolerability of Topical LFX453 for External Genital Warts

assessments and adverse event recorded. Efficacy was clinical evaluations and lesion count. During the study biopsies were taken for analysis of pharmacokinetics and biomarkers. Blood samples were taken for safety, pharmacokinetics (PK), and biomarkers. Condition or disease Intervention/treatment Phase External Genital Warts Drug: Investigational Treatment Drug: Aldara Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 88 (...) participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Randomized, Vehicle Controlled, Active Comparator, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of Topical LFX453 Formulations in Patients With External Genital Warts (EGWs) Actual Study Start Date : May 12, 2015 Actual Primary Completion Date : May 31, 2016 Actual Study Completion

2015 Clinical Trials

193. Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)

Party): Tamir Biotechnology, Inc. Study Details Study Description Go to Brief Summary: Ranpirnase in topical formulation is an antiviral drug being evaluated for the topical treatment of anogenital warts. The aims of this study is to evaluate the efficacy and safety of a topical formulation of ranpirnase in subjects with genital warts. Condition or disease Intervention/treatment Phase Condylomata Acuminata Papillomavirus Infections Sexually Transmitted Diseases Drug: Ranpirnase Drug: Vehicle Phase 1 (...) in Genital Warts - HPV Study Start Date : February 2016 Actual Primary Completion Date : September 2016 Actual Study Completion Date : September 2016 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Treatment group 1 mg/ml solution of ranpirnase applied twice daily Drug: Ranpirnase Topical application by subject Other Name: Onconase Placebo Comparator: Control Vehicle - innert gel Drug: Vehicle Vehicle

2015 Clinical Trials

194. Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer

Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02545010 Recruitment Status : Unknown Verified June 2016 by National University Hospital, Singapore. Recruitment

2015 Clinical Trials

195. Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyproneâ„¢) on the Clearance of Verruca Vulgaris (Common Warts)

, not recruiting First Posted : December 29, 2015 Last Update Posted : February 23, 2018 Sponsor: RXi Pharmaceuticals, Corp. Information provided by (Responsible Party): RXi Pharmaceuticals, Corp. Study Details Study Description Go to Brief Summary: Warts are benign epidermal tumors caused by human papillomaviruses (HPVs). The active pharmaceutical ingredient DPCP has been used for many years as a compounded formulation in acetone for the treatment of warts, alopecia areata and more recently, cutaneous (...) metastatic melanoma lesions. An improved topical ointment formulation of DPCP called Samcyprone™ will be evaluated for the treatment of common warts. Condition or disease Intervention/treatment Phase Common Warts HPV (Human Papillomavirus) Periungual Warts Plantar Warts Drug: Sensitizing DPCP Ointment Drug: Treatment DPCP Ointment Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 83 participants Allocation: Non-Randomized

2015 Clinical Trials

196. Monochloroacetic Acid Application is an Effective Alternative to Cryotherapy for Common and Plantar Warts in Primary Care: a Randomized Controlled Trial. Full Text available with Trip Pro

Monochloroacetic Acid Application is an Effective Alternative to Cryotherapy for Common and Plantar Warts in Primary Care: a Randomized Controlled Trial. Cryotherapy and salicylic acid (SA) often fail as treatments for skin warts. We examined the effectiveness of monochloroacetic acid (MCA) for patients with common or plantar warts. Consecutive patients aged 4 years and older with one or more newly diagnosed common or plantar warts were recruited in 53 Dutch general practices. We randomly (...) allocated eligible patients to 13-week treatment protocols of office-applied MCA versus liquid nitrogen cryotherapy every 2 weeks for patients with common warts (n=188), and MCA versus cryotherapy combined with daily SA self-application for patients with plantar warts (n=227). The primary outcome was the proportion of patients whose warts were all cured at 13 weeks. In the common wart group, cure rates were 40/92 (43%, 95% confidence interval 34-54) for MCA and 50/93 (54%, 44-64) for cryotherapy (risk

2015 Journal of Investigative Dermatology Controlled trial quality: predicted high

197. A Phase I/II Double-blind Study to Evaluate the Safety and Efficacy of Nowarta110 in Patients With Plantar Warts

: July 19, 2016 Last Update Posted : November 4, 2016 Sponsor: Nowarta Biopharma Inc Information provided by (Responsible Party): Nowarta Biopharma Inc Study Details Study Description Go to Brief Summary: To evaluate drug safety and efficacy in patients treated with Nowarta110 and to determine therapeutic activity against Plantar Warts Clinical Tolerance Clinical Recovery Evaluate Safety Condition or disease Intervention/treatment Phase Plantar Warts Drug: Nowarta110 Drug: Placebo Phase 1 Phase 2 (...) Detailed Description: Plantar Warts occur on the soles (plantar surface of feet) and can be severely debilitating for patients even for normal walking. The severity and magnitude of the warts can vary, but they are the cause of much pain and discomfort for all age groups. Nowarta 110 has been evaluated for the therapy of plantar warts caused by the HPV virus, (HPV infection). Clinical experience in a totals of 124 patients receiving Nowarta 110 for 5 weeks treatment in multiple clinics overseas has

2015 Clinical Trials

198. Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study Full Text available with Trip Pro

Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study Genital warts (GWs) are common, with about 5% to 10% of people having at least one episode in their lifetime. They develop about 2-3 months after infection with human papillomavirus (HPV) genotypes 6 and 11. The prophylactic quadrivalent HPV vaccine (qHPV), protects against HPV6/11 infections and diseases. In Belgium, HPV vaccines started to be reimbursed in 2007 and have been fully reimbursed (...) since December 2008 for women 12 to 18 years old. This study aimed at evaluating the real-life benefit of qHPV vaccine introduction in Belgium on GWs by measuring both vaccine impact (VI) at a population level and the direct effect of the qHPV vaccine at an individual level (vaccine effectiveness (VE)), using data from a large sick-fund (MLOZ) reimbursement database. A first reimbursement for imiquimod (most common first-line GWs treatment in Belgium) was used as a surrogate for a first GWs episode

2015 PloS one

199. Cryotherapy versus imiquimod 5% cream combined with a keratolytic lotion in cutaneous warts in children: A randomized study. (Abstract)

Cryotherapy versus imiquimod 5% cream combined with a keratolytic lotion in cutaneous warts in children: A randomized study. Although cutaneous warts are extremely common in children effective treatment does not exist. We combined imiquimod with a salicylic acid solution 15% (SA) on areas, with thick keratin, like palms and soles to increase its penetration through the epithelium.Patients were randomly divided into two groups. The first group was subjected to cryotherapy with liquid nitrogen (...) every two weeks for a maximum of 3 months. The second group was subjected to treatment with imiquimod 5% daily for 6-10 h onto the warts for five consecutive days per week for a maximum of 3 months.Eighty-six children were included, 35 girls and 51 boys, 49 in the cryotherapy group and 37 in the imiquimod and SA group. At the end of the third month no statistically significant difference could be noted between the imiquimod 5% and salicylic acid and cryotherapy groups (p = 0.154). Thirty (81.1

2015 Journal of Dermatological Treatment Controlled trial quality: uncertain

200. Evaluation of the Efficacy, Safety, and Tolerability of 3 Dose Regimens of Topical Sodium Nitrite With Citric Acid in Patients With Anogenital Warts: A Randomized Clinical Trial. Full Text available with Trip Pro

was conducted in European genitourinary medicine clinics between December 20, 2001, and January 14, 2003. Analysis was by intent to treat for all individuals initiating therapy. Participants included male and female volunteers older than 18 years with between 2 and 50 external anogenital warts. A total of 299 individuals from 40 centers were randomized to a control arm and a treatment arm that received 3 doses of acidified nitrite applied topically for 12 weeks with an additional 12 weeks of follow-up (...) with complete clinical clearance of target warts; secondary outcomes were reduction in target wart area and safety.Complete clinical clearance at 12 weeks occurred in 10 of 74 patients (14%; 95% CI, 6%-21%) with placebo; 11 of 72 (15%; 95% CI, 7%-24%) with low-dose treatment; 17 of 74 (23%; 95% CI, 13%-33%) with middle-dose treatment; and 22 of 70 (31%; 95% CI, 21%-42%) with high-dose treatment (P = .01). Reduction in target wart area, time to clearance, and patient and investigator assessments supported

2015 JAMA dermatology Controlled trial quality: predicted high

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>